{"schema":"hottub-news/story/v1","story":"st_ez2333tdkevrdkr7vwsa","title":"Emugrobar、肥満症での開発を中止しSMAで開発再開","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/emugrobar-sma-ez2333tdke","count":1,"items":[{"id":"n_ez2333tdkevrdkr7vwsa","seq":562005,"kind":"article","title":"Emugrobar、肥満症での開発を中止しSMAで開発再開","url":"https://medical-tribune.co.jp/rensai/articles?blogid=11&entryid=616208","summary":"中外製薬は昨日（9月28日）、自社が創出しスイス・ロシュが開発中の潜在型ミオスタチンスイーピング抗体emugrobart（開発コードGYM329）について、肥満症を対象とした臨床開発を中止し、ロシュによる同薬の開発を終了することを決定したと発表した。これに伴い同薬に関する全てのライセンス権が中外製薬に返還される。 今回の決定は、肥満症患者を対象に実施中の第Ⅱ相GYMINDA試験の中間解析結果を含...","published":"2026-09-29T02:30:47Z","seen":"2026-09-29T02:30:47Z","lang":"en","source":{"id":"kite-medical-tribune-co-jp-14fcf3","name":"medical-tribune.co.jp","domain":"medical-tribune.co.jp"},"via":"kite-medical-tribune-co-jp-14fcf3","topics":["medicine","新薬エクスプレス"],"entities":[{"id":"Q580290","name":"spinal muscular atrophy","type":"other"}],"image":"https://asset.mtweb.jp/media/2026/09/14145140/com_pressb_thum_w440h275-2.jpg","story":"st_ez2333tdkevrdkr7vwsa","category":"health","category_p":0.49000000953674316,"category2":"economy-business","sentiment":"neutral","tone":0.10000000149011612,"political":0.019999999552965164}]}